Hard to Treat Diseases (the "Company") (HTDS.PK) announced today that it has closed its Regulation D, Rule 504 offering and is no longer selling shares of its common stock to accredited investors. A Form D will be filed with the Securities and Exchange Commission shortly, disclosing that the company has raised $990,000 in the offering over the past twelve months. The limit to any such offering is $1 million per year.
HTDS is a holding company for China-based Shenzhen Mellow Hope Pharm Industrial Co., Ltd. Mellow Hope is the biggest exporter of biological vaccines in China. Based on the cooperation with Institutes of Medical Biology and pharmaceutical manufacturers, Mellow Hope provides a wide range of vaccines with high quality, safety and efficacy. HTDS' other controlling interests include an East European (Serbian) medical company, Slavica Biochem, whose experts are performing cutting edge research in the field of neurological impairments in Multiple Sclerosis (MS) and Traumatic Brain Injury (TBI). The primary focus of Slavica Biochem is to investigate novel therapeutic approaches in treatment of these disorders of the CNS (central nervous system), as well as to enhance and modify existing approved drugs such as VIRAZOLE(R).